You are about to enter factorthinktank.com
This information is for European and UK healthcare professionals only
Are you a European or UK healthcare professional?
By selecting ‘No’, you will be diverted to www.sobi.com/en/haemophilia
Non-severe haemophilia
Non-severe haemophilia workstream
Paediatric haemophilia
workstream
Non-severe haemophilia
workstream
Joint health
workstream
Haemophilia B
workstream
Dr Gerry Dolan, MD, MBChB, FRCP, FRCPath
Centre for Haemostasis and Thrombosis, St Thomas’ Comprehensive Care Centre, London, UK
Gerry Dolan is a consultant haematologist and haemophilia centre director at St Thomas’ Comprehensive Care Centre, London, UK, and former centre director at Nottingham University Hospitals, Nottingham, UK. He is former chairman of the UK Haemophilia Centre Directors and president of the British Society for Haemostasis & Thrombosis. He has been an active participant in collaborative European initiatives in haemophilia and has chaired initiatives such as the ADVANCE group and the European Haemophilia Therapy Standardisation Board. His interests include novel agents in the treatment of haemophilia, gene therapy and clinical outcomes.
Dr Cristina Catarino, MD, PhD
Immunochemotherapy Department, Congenital Coagulopathies Comprehensive Care Centre, Santa Maria University Hospital, Lisbon University, Lisbon, Portugal
Cristina Catarino is a specialist in immunohaemotherapy and transfusion medicine. She is head of the Congenital Coagulopathies Comprehensive Care Centre of Santa Maria’s Hospital, Lisbon, Portugal. She has coauthored national guidelines for the treatment of congenital and acquired coagulopathies and is a medical advisor to the Portuguese Association of Haemophilia whom she represents in the European Haemophilia Consortium.
Prof. Karin Fijnvandraat, MD, PhD
Paediatric Haematology, Emma Children’s Hospital, and UMC, University of Amsterdam, Amsterdam, Netherlands
Karin Fijnvandraat is director of the Haemophilia Treatment Centre in Amsterdam, Netherlands. Her clinical focus is on haemophilia, allied bleeding disorders and sickle cell disease. Her research in haemophilia focuses on phenotypic heterogeneity and inhibitor development in mild haemophilia A. She has contributed to many multicentre studies on haemophilia, von Willebrand disease, neonatal transfusion and sickle cell disease.
Dr Michelle Lavin, MB BCh BAO, PhD, FRCPath
Irish Centre for Vascular Biology, School of Pharmacy and Biomedical Sciences, Royal College of Surgeons in Ireland and National Coagulation Centre, St. James’s Hospital, Dublin, Ireland
Michelle Lavin is a consultant haematologist at the National Coagulation Centre, St. James’s Hospital, Dublin, Ireland, and a researcher at the Irish Centre for Vascular Biology at the Royal College of Surgeons in Ireland. Her research focuses on improving diagnostic pathways and clinical outcomes for those with mild bleeding disorders, with a particular interest in women and girls with bleeding disorders.